
Microsoft alerts businesses and governments to attacks on SharePoint servers
The Federal Bureau of Investigation said Sunday it is aware of the attacks and is working closely with its federal and private sector partners, but offered no other details.
In an alert issued Saturday, Microsoft (MSFT) said the vulnerabilities apply only to SharePoint servers used within organizations. It said SharePoint Online in Microsoft 365, which is in the cloud, was not hit by the attacks.
'We've been coordinating closely with CISA, DOD Cyber Defense Command and key cybersecurity partners globally throughout our response,' a Microsoft spokesperson said, adding that the company had issued security updates and urged customers to install them immediately.
The Washington Post, which first reported the hacks, said unidentified actors in the past few days had exploited a flaw to launch an attack that targeted US and international agencies and businesses.
The hack is known as a 'zero day' attack because it targeted a previously unknown vulnerability, the newspaper said, quoting experts. Tens of thousands of servers were at risk.
In the alert, Microsoft said that a vulnerability 'allows an authorized attacker to perform spoofing over a network.' It issued recommendations to stop the attackers from exploiting it.
In a spoofing attack, an actor can manipulate financial markets or agencies by hiding the actor's identity and appearing to be a trusted person, organization or website.
Earlier, Microsoft said it is working on updates to 2016 and 2019 versions of SharePoint. If customers cannot enable recommended malware protection, they should disconnect their servers from the internet until a security update is available, it added.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Yahoo
22 minutes ago
- Yahoo
West Pharma raises annual profit forecast on strong demand for its drug components
(Reuters) -Medical equipment maker West Pharmaceutical raised its annual profit forecast on Thursday, after topping second-quarter estimates on robust demand for its components used in GLP-1 weight-loss and diabetes drugs as well as a weaker dollar. The Pennsylvania-based firm's shares rose 16.8% to $264 premarket following the results. The company's drug components business, which makes up 47% of its total sales, saw a rise in demand amid sales growth in high-margin products. It also credited normalized customer ordering patterns for its quarterly performance. West Pharma's products are used by major pharmaceutical firms, including Eli Lilly and Novo Nordisk, in the administration of a wide range of therapies. The company supplies components such as stoppers, plungers and delivery systems that are critical to the safe packaging and administration of vaccines, biologics and other injectable medicines. West Pharma, which generates about half of its revenue from international markets, flagged a $20 million to $25 million hit to its earnings in April due to U.S. President Donald Trump's shifting trade policies. However, its second-quarter sales rose 9.2% to $766.5 million from a year ago, beating analysts' average estimate of $727.5 million, according to data compiled by LSEG. The company posted quarterly profit of $1.84 per share on an adjusted basis, above expectations of $1.51. West Pharma expects 2025 adjusted profit between $6.65 and $6.85 per share, up from the prior view of $6.15 to $6.35. The medical equipment maker also raised its annual sales forecast to a range of $3.04 billion to $3.06 billion, compared with an earlier projection of $2.95 billion to $2.98 billion.
Yahoo
22 minutes ago
- Yahoo
Nexusguard positioned as a Leader in the SPARK Matrix™: Distributed Denial of Service (DDoS) Mitigation, 2025 by QKS Group
Nexusguard, with its DDoS Mitigation solution, has received strong ratings across technology excellence and customer impact. Pune India, July 24, 2025 (GLOBE NEWSWIRE) -- QKS Group announced today that it has named Nexusguard as a leader in the SPARK Matrix™: Distributed Denial of Service (DDoS) Mitigation, 2025. Lokesh Biswal, Analyst at QKS Group, states, " Nexusguard offers AI-driven DDoS mitigation for CSPs, blending global scrubbing centers with on-prem Bastions. Its modular platform supports branded, multi-layered protection and real-time response for critical services. The QKS Group SPARK Matrix™ includes analysis of the global market dynamics, trends, vendor landscape, and competitive positioning. The study also provides a competitive analysis and ranking of the Distributed Denial of Service Mitigation providers in the form of the SPARK Matrix™. We're proud to be named a Leader in the SPARK Matrix™ for DDoS Mitigation. From our roots to now serving 100+ ISPs globally, our focus has remained on the evolving needs of Communications Service Providers. This recognition highlights both our innovation and the market's move toward telco-focused, scalable mitigation. As threats grow, we stay committed to helping CSPs deliver the protection and performance their customers expect. By Donny Chong, Product Director of Nexusguard. Additional Resources: For more information about Nexusguard, visit SPARK Matrix™ Distributed Denial of Service (DDoS) Mitigation, 2025 About Nexusguard: Established in 2008, Nexusguard operates globally with its headquarters in Singapore. Nexusguard is a trusted provider of DDoS protection solutions, dedicated to helping enterprises and CSPs safeguard their networks, web applications, and DNS from malicious attacks. Leveraging our proprietary Bastions DDoS defense technology and a global network of over 50 DDoS scrubbing centers, we deliver reliable, scalable solutions that ensure service availability and operational continuity. Trusted by more than 100 CSPs including some of the top 10 CSPs in the world, and protecting over 50,000 ASNs, Nexusguard secures organizations worldwide against evolving threats with comprehensive and proactive protection. Visit Media Contacts: Benjamin Yip Head of Marketing Media@ About QKS Group QKS Group is a global advisory and consulting firm that empowers organizations to achieve business transformation through strategic growth guidance. Our research-driven insights help clients navigate change, seize opportunities, and build resilient, forward-looking strategies. For more available research, please visit Research Media Contacts: QKS Group Shraddha Roy Email: shraddha.r@ Content Source: with us on LinkedIn- CONTACT: Media Contacts: QKS Group Shraddha Roy Email: shraddha.r@
Yahoo
22 minutes ago
- Yahoo
Laughing Water Capital's View on Lifecore Biomedical (LFCR)
Laughing Water Capital, an investment management company, released its second-quarter 2025 investor letter. A copy of the letter can be downloaded here. In the second quarter of 2025, Class A interests in Laughing Water Capital returned approximately 13.1% net of all expenses. The SP500TR and R2000 returned 10.9% and 8.5%, respectively. In addition, you can check the fund's top 5 holdings to determine its best picks for 2025. In its second quarter 2025 investor letter, Laughing Water Capital highlighted stocks such as Lifecore Biomedical, Inc. (NASDAQ:LFCR). Lifecore Biomedical, Inc. (NASDAQ:LFCR) is an integrated contract development and manufacturing organization. The one-month return of Lifecore Biomedical, Inc. (NASDAQ:LFCR) was -8.51%, and its shares gained 24.05% of their value over the last 52 weeks. On July 23, 2025, Lifecore Biomedical, Inc. (NASDAQ:LFCR) stock closed at $7.53 per share, with a market capitalization of $278.801 million. Laughing Water Capital stated the following regarding Lifecore Biomedical, Inc. (NASDAQ:LFCR) in its second quarter 2025 investor letter: "Lifecore Biomedical, Inc. (NASDAQ:LFCR) – Lifecore, our fill-finish CDMO, continues to work toward their dual goals of increasing capacity utilization and expanding margins. I continue to believe that achieving these goals is very much a 'when' rather than an 'if.' This belief was founded on global supply and demand dynamics, strengthened by the BIOSECURE Act, and reinforced by the National Security Commission delivering a report and action plan to Congress, which calls for the re-shoring of the biotech supply chain. To top it off, Trump has recently stated that pharmaceuticals manufactured abroad will be subject to 200% tariffs. Considering that building and certifying new fill-finish capacity can take 4 or 5 years, it seems that it would be much easier to partner with a company like Lifecore. A village pharmacist fulfilling a patient's medication prescription in a rural area. Lifecore Biomedical, Inc. (NASDAQ:LFCR) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 12 hedge fund portfolios held Lifecore Biomedical, Inc. (NASDAQ:LFCR) at the end of the first quarter compared to 10 in the previous quarter. In the fiscal third quarter of fiscal 2025, Lifecore Biomedical, Inc. (NASDAQ:LFCR) generated $35.2 million in revenues compared to $35.7 million for the comparable 2024 period. While we acknowledge the potential of Lifecore Biomedical, Inc. (NASDAQ:LFCR) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. In another article, we covered Lifecore Biomedical, Inc. (NASDAQ:LFCR) and shared Greenhaven Road Capital's views on the company in the company. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio